Ichnos Sciences, in collaboration with Glenmark Pharmaceuticals, focuses on developing innovative therapies for hematological malignancies and solid tumors. Their approach leverages a proprietary protein engineering platform that enables the creation of full-length multispecific antibodies, providing flexibility and manufacturability. This technology is designed to enhance immune cell engagement across various cancer types, thereby improving treatment outcomes. The company emphasizes a robust discovery engine that supports ongoing innovation and long-term growth in oncology.

The organization operates three state-of-the-art Centers of Innovation located in the USA, Switzerland, and India, which are dedicated to clinical development and early-stage research. Their pipeline includes several promising candidates currently in Phase 1 trials, such as ISB 1442 and ISB 2001, which target specific cancer markers. Ichnos Sciences is committed to pushing the boundaries of cancer treatment through collaboration and a highly experienced team, aiming to provide new hope for patients and healthcare professionals alike.

United States

Ichnos Sciences is a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology and disease-centric therapies.

Ichnos Sciences

Company Details